These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. Carrascosa A, Audí L, Fernández-Cancio M, Esteban C, Andaluz P, Vilaró E, Clemente M, Yeste D, Albisu MA, Gussinyé M. J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465 [Abstract] [Full Text] [Related]
3. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ. J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702 [Abstract] [Full Text] [Related]
5. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children. Carrascosa A, Audí L, Esteban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA. J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340 [Abstract] [Full Text] [Related]
6. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S. J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057 [Abstract] [Full Text] [Related]
8. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L, Spanish SGA Study Group. J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042 [Abstract] [Full Text] [Related]
9. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. Audí L, Carrascosa A, Esteban C, Fernández-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L, Spanish SGA Study Group. J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665 [Abstract] [Full Text] [Related]
13. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Meyer S, Schaefer S, Stolk L, Arp P, Uitterlinden AG, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Kann PH. Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933 [Abstract] [Full Text] [Related]